ResMed Inc. (ASX:RMD)
37.82
+0.32 (0.85%)
At close: Dec 2, 2025
ResMed Revenue
ResMed had revenue of $1.34B USD in the quarter ending September 30, 2025, with 9.07% growth. This brings the company's revenue in the last twelve months to $5.26B, up 9.36% year-over-year. In the fiscal year ending June 30, 2025, ResMed had annual revenue of $5.15B with 9.84% growth.
Revenue (ttm)
$5.26B
Revenue Growth
+9.36%
P/S Ratio
6.96
Revenue / Employee
$495.98K
Employees
10,600
Market Cap
55.34B AUD
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 5.15B | 461.03M | 9.84% |
| Jun 30, 2024 | 4.69B | 462.30M | 10.95% |
| Jun 30, 2023 | 4.22B | 644.87M | 18.02% |
| Jun 30, 2022 | 3.58B | 381.30M | 11.93% |
| Jun 30, 2021 | 3.20B | 239.81M | 8.11% |
| Jun 30, 2020 | 2.96B | 350.44M | 13.44% |
| Jun 30, 2019 | 2.61B | 266.38M | 11.38% |
| Jun 30, 2018 | 2.34B | 273.46M | 13.23% |
| Jun 30, 2017 | 2.07B | 228.02M | 12.40% |
| Jun 30, 2016 | 1.84B | 159.80M | 9.52% |
| Jun 30, 2015 | 1.68B | 123.94M | 7.97% |
| Jun 30, 2014 | 1.55B | 40.52M | 2.68% |
| Jun 30, 2013 | 1.51B | 145.94M | 10.66% |
| Jun 30, 2012 | 1.37B | 125.37M | 10.08% |
| Jun 30, 2011 | 1.24B | 150.79M | 13.80% |
| Jun 30, 2010 | 1.09B | 171.62M | 18.64% |
| Jun 30, 2009 | 920.74M | 85.34M | 10.22% |
| Jun 30, 2008 | 835.40M | 119.07M | 16.62% |
| Jun 30, 2007 | 716.33M | 109.34M | 18.01% |
| Jun 30, 2006 | 607.00M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| CSL Limited | 23.73B |
| Ramsay Health Care | 17.79B |
| Sonic Healthcare | 9.65B |
| Ansell | 3.06B |
| Cochlear | 2.34B |
| Regis Healthcare | 1.16B |
| Telix Pharmaceuticals | 1.01B |
| Neuren Pharmaceuticals | 218.86M |
ResMed News
- 1 day ago - ResMed (RMD) Dropped from Goldman Sachs' APAC Conviction List - GuruFocus
- 5 days ago - PETER FARRELL At ResMed Acquires Stock Options Worth $7K - Benzinga
- 5 days ago - Michael J Farrell Makes Strategic Play: Invests $179K In ResMed Stock Options - Benzinga
- 5 days ago - Insider Sell: Witte De Sells 2,055 Shares of ResMed Inc (RMD) - GuruFocus
- 7 days ago - IDEXX Laboratories Vs ResMed: Which Stock Could Rally? - Forbes
- 11 days ago - ResMed Inc. (RMD) Announces Key Amendments to Incentive and Stock Purchase Plans - GuruFocus
- 13 days ago - Peter C Farrell Exercises Options, Realizes $1.65M - Benzinga
- 13 days ago - Noteworthy Tuesday Option Activity: AAPL, NVDA, RMD - Nasdaq